Edition:
United States

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

0.62USD
4:00pm EDT
Change (% chg)

$0.05 (+8.72%)
Prev Close
$0.57
Open
$0.57
Day's High
$0.63
Day's Low
$0.56
Volume
30,518
Avg. Vol
142,229
52-wk High
$5.61
52-wk Low
$0.56

Chart for

About

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one... (more)

Overall

Beta: 0.95
Market Cap(Mil.): $51.11
Shares Outstanding(Mil.): 86.63
Dividend: --
Yield (%): --

Financials

  GNCA.OQ Industry Sector
P/E (TTM): -- 169.61 31.56
EPS (TTM): -1.24 -- --
ROI: -132.16 1.42 12.88
ROE: -296.13 0.52 15.04

BRIEF-Genocea Biosciences Files For Mixed Shelf Of Up To $200 Mln

* GENOCEA BIOSCIENCES INC - FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (https://bit.ly/2GBQyfr) Further company coverage:

May 21 2018

BRIEF-Genocea Reports Qtrly Loss Per Share $0.21

* GENOCEA REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

May 10 2018

BRIEF-Genocea Biosciences Enters Into Term Loan Facility Of $14 Million With Hercules

* GENOCEA BIOSCIENCES INC - ON APRIL 24, CO ENTERED INTO TERM LOAN FACILITY OF $14 MILLION WITH HERCULES

Apr 30 2018

BRIEF-Genocea Files IND For Neoantigen Cancer Vaccine Candidate Gen-009

* GENOCEA - FILES IND FOR NEOANTIGEN CANCER VACCINE CANDIDATE GEN-009, PLANS TO INITIATE PHASE 1/2A CLINICAL PROGRAM LATER THIS YEAR

Apr 30 2018

BRIEF-Genocea Biosciences Says Jonathan Poole Delivered Resignation As CFO

* GENOCEA BIOSCIENCES - ‍ON MARCH 6, JONATHAN POOLE DELIVERED RESIGNATION AS CFO EFFECTIVE MARCH 23, 2018​

Mar 09 2018

BRIEF-Genocea Qtrly Loss Per Share $0.37

* GENOCEA REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Feb 15 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF81.52 -0.16
Pfizer Inc. (PFE.N) $40.71 -0.10
Merck & Co., Inc. (MRK.N) $66.46 -0.26
Sanofi SA (SASY.PA) €72.85 --
AstraZeneca plc (AZN.L) 6,015.00 -37.00
GlaxoSmithKline plc (GSK.L) 1,560.00 +9.20
Vical Incorporated (VICL.OQ) $1.30 -0.01

Earnings vs. Estimates